Table 3

Assessments
Investigations Timing
History and Physical Exam including: · Height (baseline only) 0,2,4, 6 months
· Weight and Body Mass Index (BMI)
· Blood Pressure and Heart Rate
· Oxygen saturation (SaO2) (on room air)
· Concomitant medications (any changes to baseline meds)
· Colinet Co-morbidity Score
· Eastern Cooperative Oncology Group Performance Status (ECOG PS)
· Disease status
· Current treatments
Fitness Testing · 6-minute walk test (6MWT) 0,2,4, 6,months
· Senior’s Fitness Test
· Hand grip strength
Pulmonary Function · Forced Expiratory Volume at 1 second (FEV1) 0,2,4,6 months
· Forced Vital Capacity (FVC)
Adverse Events · Adverse events will be recorded and graded using National Cancer Institute Common Terminology Criteria for Adverse Events Version 3.0 (NCI CTCAE v3.0) 0,2,4, 6 months
Patient Reported Outcomes · Functional Assessment of Cancer Therapy - Fatigue (FACT-F subscale) 0,2,4,6 months
· Quality of Life (QOL) European Organisation for Research and Treatment of Cancer –Quality of life questionnaire – Core (EORTC-QLQ-C30) and Lung module (LC-13 subscale)
· Depression and Anxiety (General Health Questionnaire - GHQ12)
· Sleep Quality (Pittsburgh Sleep Quality Index - PSQI)
· Cognitive Function (Functional Assessment of Cancer Therapy – Cognitive scale - FACT-COG v3)
· Distress (Distress Thermometer)
· Dyspnoea (The University of California, San Diego Shortness of Breath Questionnaire -SOBQ)
· Activities of Daily Living (ADLs) and Independent Activities of Daily Living (IADLs)
· Sedentary time (Sitting Questionnaire)
· Physical activity attitudes (Social Cognitive Determinants of Exercise questionnaire)
Physical Activity Behaviour/ Adherence · Physical activity participation (Active Australia) 0,2,4, 6 months
· Accelerometer -for one week prior to each assessment
Other Investigations · Fasting Serum/plasma collection for correlative studies and optional banking 0,2,4,6 months
· Glasgow Prognostic score: Full blood count (FBC), Albumin, C-reactive protein (CRP)

Dhillon et al.

Dhillon et al. BMC Cancer 2012 12:572   doi:10.1186/1471-2407-12-572

Open Data